Post-traumatic stress disorder (PTSD) is a common condition that can develop after traumatic events such as accidents, war, abuse, or domestic violence. Current treatments, combining trauma-focused psychotherapy with selective serotonin reuptake inhibitors (SSRIs), are often insufficient. This review of literature from 2000–2023 found that MDMA (ecstasy)-assisted therapy shows promising results for treating PTSD, with a satisfactory safety profile. The improvement likely stems from MDMA's effects on brain regions involved in threat detection and emotion processing. More research is needed, especially direct comparisons with SSRIs and long-term safety assessments.
Psilocybin, a classic psychedelic found in magic mushrooms, has been used for centuries in religious ceremonies and is now being studied for treating psychiatric disorders. Recent research suggests psilocybin may effectively treat cancer-related psychiatric distress, treatment-resistant depression, and addiction, with some reports indicating usefulness for obsessive-compulsive disorder and cluster headaches. Psychological support during treatment is crucial. More large-scale, randomized, placebo-controlled studies are needed to confirm these promising findings.